Una Sibirceva MD, PC

Una Sibirceva MD, PC was paid $2.45M by Medicaid between Jan 2018 and Nov 2024, across 21 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 39% of everything it billed.

33Billing provider infoUNA SIBIRCEVA MD, PC
BROOKLYN, NY 11235

33aNPI1154631562assigned 10/19/2010

33bProvider typePain Medicine (Anesthesiology) Physician

28Total paid$2.45M

24GClaims32,150

24DCodes billed21

24AFirst – last monthJan 2018 – Nov 2024

Compared with peers

Next to other Pain Medicine (Anesthesiology) Physician providers in New York

Rank by total paid#5 of 125

Median peer was paid$14K

This provider vs. median175×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,963	$476K
2019	5,653	$449K
2020	4,482	$338K
2021	5,679	$503K
2022	6,032	$421K
2023	4,120	$262K
2024incomplete	221	$1K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	39%	14,964	13,213	$948K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	12%	2,652	2,648	$293K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	12%	6,464	6,450	$291K
62323		8.9%	975	972	$218K
64483		7.9%	983	978	$193K
64484		3.6%	982	977	$88K
95910		3.4%	675	665	$83K
64493		3.3%	542	529	$81K
95886		3.0%	1,119	709	$74K
64495		1.7%	540	527	$40K
64494		1.6%	542	529	$40K
93925		<1%	103	103	$19K

9 more codes

93970		<1%	123	$18K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	240	$15K
99483	Prolong outpt/office vis	<1%	83	$15K
99204	Doctor's office visit, new patient (more involved)	<1%	93	$12K
99214	Doctor's office visit, returning patient (more involved)	<1%	116	$9K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	651	$9K
G0396	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes	<1%	64	$1K
G0505	Cognition and functional assessment using standardized instruments with development of recorded care plan for the patient with cognitive impairment, history obtained from patient and/or caregiver, in office or other outpatient setting or home or domiciliary or rest home	<1%	17	$1K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	222	$218.92

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGORSHKOV, STAN (OFFICE MANADGER)